GSK
About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Employees: 68,629
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
339% more call options, than puts
Call options by funds: $460M | Put options by funds: $105M
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
0.76% more ownership
Funds ownership: 7.48% [Q3] → 8.24% (+0.76%) [Q4]
7% less funds holding
Funds holding: 888 [Q3] → 830 (-58) [Q4]
9% less capital invested
Capital invested by funds: $12.6B [Q3] → $11.6B (-$1.08B) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 282 | Existing positions reduced: 318
30% less first-time investments, than exits
New positions opened: 103 | Existing positions closed: 148
Research analyst outlook
We haven’t received any recent analyst ratings for GSK.
Financial journalist opinion
Based on 112 articles about GSK published over the past 30 days
Positive
CNBC
5 hours ago
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Positive
Zacks Investment Research
8 hours ago
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
Neutral
Seeking Alpha
9 hours ago
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown.
Positive
Zacks Investment Research
10 hours ago
Here's Why GSK (GSK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
GlobeNewsWire
11 hours ago
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections.
Positive
Benzinga
12 hours ago
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had estimated sales of $7.46 billion.
Positive
Investors Business Daily
12 hours ago
GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs
GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales.
Positive
Investopedia
12 hours ago
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.
Positive
Proactive Investors
12 hours ago
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
Positive
Zacks Investment Research
13 hours ago
GSK (GSK) Q1 Earnings Surpass Estimates
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.
Charts implemented using Lightweight Charts™